These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 35377645)

  • 1. Proteostasis Regulators in Cystic Fibrosis: Current Development and Future Perspectives.
    Brusa I; Sondo E; Falchi F; Pedemonte N; Roberti M; Cavalli A
    J Med Chem; 2022 Apr; 65(7):5212-5243. PubMed ID: 35377645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
    Amico G; Brandas C; Moran O; Baroni D
    Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NBD2 Is Required for the Rescue of Mutant F508del CFTR by a Thiazole-Based Molecule: A Class II Corrector for the Multi-Drug Therapy of Cystic Fibrosis.
    Brandas C; Ludovico A; Parodi A; Moran O; Millo E; Cichero E; Baroni D
    Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An overview on chemical structures as ΔF508-CFTR correctors.
    Spanò V; Montalbano A; Carbone A; Scudieri P; Galietta LJV; Barraja P
    Eur J Med Chem; 2019 Oct; 180():430-448. PubMed ID: 31326599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unravelling druggable signalling networks that control F508del-CFTR proteostasis.
    Hegde RN; Parashuraman S; Iorio F; Ciciriello F; Capuani F; Carissimo A; Carrella D; Belcastro V; Subramanian A; Bounti L; Persico M; Carlile G; Galietta L; Thomas DY; Di Bernardo D; Luini A
    Elife; 2015 Dec; 4():. PubMed ID: 26701908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptomic and Proteostasis Networks of CFTR and the Development of Small Molecule Modulators for the Treatment of Cystic Fibrosis Lung Disease.
    Strub MD; McCray PB
    Genes (Basel); 2020 May; 11(5):. PubMed ID: 32414011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cystic Fibrosis: Proteostatic correctors of CFTR trafficking and alternative therapeutic targets.
    Hanrahan JW; Sato Y; Carlile GW; Jansen G; Young JC; Thomas DY
    Expert Opin Ther Targets; 2019 Aug; 23(8):711-724. PubMed ID: 31169041
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of Fused Pyrrolothiazole Systems as Correctors of Mutant CFTR Protein.
    Spanò V; Barreca M; Cilibrasi V; Genovese M; Renda M; Montalbano A; Galietta LJV; Barraja P
    Molecules; 2021 Feb; 26(5):. PubMed ID: 33652850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CFTR Folding: From Structure and Proteostasis to Cystic Fibrosis Personalized Medicine.
    McDonald EF; Meiler J; Plate L
    ACS Chem Biol; 2023 Oct; 18(10):2128-2143. PubMed ID: 37730207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CFTR processing, trafficking and interactions.
    Amaral MD; Hutt DM; Tomati V; Botelho HM; Pedemonte N
    J Cyst Fibros; 2020 Mar; 19 Suppl 1():S33-S36. PubMed ID: 31680043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment.
    Capurro V; Tomati V; Sondo E; Renda M; Borrelli A; Pastorino C; Guidone D; Venturini A; Giraudo A; Mandrup Bertozzi S; Musante I; Bertozzi F; Bandiera T; Zara F; Galietta LJV; Pedemonte N
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34067708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting CFTR: how to treat cystic fibrosis by CFTR-repairing therapies.
    Amaral MD
    Curr Drug Targets; 2011 May; 12(5):683-93. PubMed ID: 21039334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls.
    Bell SC; De Boeck K; Amaral MD
    Pharmacol Ther; 2015 Jan; 145():19-34. PubMed ID: 24932877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CFTR: folding, misfolding and correcting the ΔF508 conformational defect.
    Lukacs GL; Verkman AS
    Trends Mol Med; 2012 Feb; 18(2):81-91. PubMed ID: 22138491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1.
    Ren HY; Grove DE; De La Rosa O; Houck SA; Sopha P; Van Goor F; Hoffman BJ; Cyr DM
    Mol Biol Cell; 2013 Oct; 24(19):3016-24. PubMed ID: 23924900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of thiazole derivatives on basic defects underlying cystic fibrosis.
    Pesce E; Pedemonte N; Leoni A; Locatelli A; Morigi R
    Bioorg Med Chem Lett; 2020 Nov; 30(21):127473. PubMed ID: 32784089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decoding F508del misfolding in cystic fibrosis.
    Wang XR; Li C
    Biomolecules; 2014 May; 4(2):498-509. PubMed ID: 24970227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thymosin α-1 does not correct F508del-CFTR in cystic fibrosis airway epithelia.
    Tomati V; Caci E; Ferrera L; Pesce E; Sondo E; Cholon DM; Quinney NL; Boyles SE; Armirotti A; Ravazzolo R; Galietta LJ; Gentzsch M; Pedemonte N
    JCI Insight; 2018 Feb; 3(3):. PubMed ID: 29415893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correcting CFTR folding defects by small-molecule correctors to cure cystic fibrosis.
    Mijnders M; Kleizen B; Braakman I
    Curr Opin Pharmacol; 2017 Jun; 34():83-90. PubMed ID: 29055231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.